Congress trades
BioNTech SE (BNTX)
Free on iOS and Android.
About BioNTech SE
from the company's filings and listing, as of Oct 26, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Ugur Sahin
- Employees
- 7,807
- Listed since
- Oct 10, 2019
- Market value
- $22.1B
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -
- Dividend yield
- -
www.biontech.com/de/de/home.html
Earnings
6 reported quarters · next on Nov 3, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 4, 2026 | -$3.70 | -$2.40 | $120.6M | $180.2M | EPS missRevenue miss |
| Q1 FY2026reported May 5, 2026 | -$2.43 | -$2.54 | $136.4M | $207.4M | EPS beatRevenue miss |
| Q4 FY2025reported Mar 10, 2026 | -$1.44 | -$0.22 | $1.1B | $902.3M | EPS missRevenue beat |
| Q3 FY2025reported Nov 3, 2025 | -$0.14 | -$1.12 | $1.8B | $843.7M | EPS beatRevenue beat |
| Q2 FY2025reported Aug 4, 2025 | -$1.82 | -$2.69 | $307.1M | $177.8M | EPS beatRevenue beat |
| Q1 FY2025reported May 5, 2025 | -$1.82 | -$2.48 | $200.4M | $215.1M | EPS beatRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| FMR LLC | $704.6M | 7,571,805 | +32.6% | 2.99% |
| Primecap Management Co | $351.0M | 3,772,031 | -0.6% | 1.49% |
| Dodge & Cox | $342.2M | 3,677,591 | 0.0% | 1.45% |
| Flossbach Von Storch SE | $207.1M | 2,226,138 | -39.5% | 0.88% |
| T. Rowe Price Investment Management, Inc. | $192.2M | 2,065,456 | -64.7% | 0.82% |
| BlackRock, Inc. | $172.6M | 1,854,966 | +11.9% | 0.73% |
| Temasek Holdings (Private) Ltd | $140.1M | 1,506,027 | 0.0% | 0.59% |
| BNP Paribas Arbitrage, SNC | $122.8M | 1,319,517 | -20.1% | 0.52% |
| Logos Global Management LP | $94.4M | 1,015,000 | New | 0.40% |
| GSK PLC | $82.8M | 889,824 | 0.0% | 0.35% |
| First Trust Advisors LP | $73.6M | 791,469 | -5.8% | 0.31% |
| Davern Capital Partners, LP | $70.2M | 754,550 | +147.3% | 0.30% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in BNTX
9 disclosures of 9 on record · median 30d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Val T. HoyleSpouse | Stock | Sale | $1,001 - $15,000 | -20.9%After the saleS&P 500 +20.2% · -41.0 pts vs S&P 500 | Aug 7, 2025 | Sep 12, 2025 | 36d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +0.1%After the saleS&P 500 +37.6% · -37.5 pts vs S&P 500 | Sep 3, 2024 | Oct 3, 2024 | 30d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -0.1%After the saleS&P 500 +34.9% · -35.0 pts vs S&P 500 | Aug 30, 2024 | Sep 11, 2024 | 12d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +0.3%S&P 500 +50.7% · -50.4 pts vs S&P 500 | Apr 15, 2024 | May 15, 2024 | 30d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -5.2%After the saleS&P 500 +47.6% · -52.8 pts vs S&P 500 | Mar 14, 2024 | Apr 7, 2024 | 24d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -10.8%S&P 500 +66.5% · -77.2 pts vs S&P 500 | Dec 5, 2023 | Jan 7, 2024 | 33d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -13.0%S&P 500 +67.2% · -80.2 pts vs S&P 500 | Dec 6, 2023 | Jan 7, 2024 | 32d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -13.5%S&P 500 +65.9% · -79.4 pts vs S&P 500 | Dec 7, 2023 | Jan 7, 2024 | 31d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -43.7%After the saleS&P 500 +70.1% · -113.8 pts vs S&P 500 | Jan 20, 2022 | Feb 8, 2022 | 19d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in BNTX, filterable by party, chamber, type and account.
Questions
Which members of Congress have traded BNTX?
Val T. Hoyle, Josh Gottheimer and Ro Khanna disclosed BNTX transactions in the filings shown here.
How quickly are BNTX trades disclosed?
Congressional disclosures took a median of 30 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.